he FDA is digging into the data on a revolutionary new approach to treating cancer. At stake: billions of dollars for pharma giant Novartis, a blockbuster race among biotech startups, and a potential breakthrough for patients with aggressive forms of cancer.
Join STAT’s Adam Feuerstein and Damian Garde plus EP Vantage’s Jacob Plieth for an all-day live blog of the make-or-break meeting, starting at 8 a.m. ET.
The live blog is now closed. You can access the archive below.